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OBJECTIVES We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial
infarction (AMI) treated with thrombolysis.
BACKGROUND The role of ticlopidine in secondary prevention after AMI has not yet been explored.
METHODS Of 4,696 patients with AMI treated with thrombolysis who were screened, 261 died in the
hospital (5.6%) and 1,470 were enrolled in this randomized, double-blind, multicenter trial
and allocated to treatment with either aspirin (160 mg/day) or ticlopidine (500 mg/day). The
most frequent reasons for exclusion were refusal to give informed consent, planned myocardial
revascularization, risk of noncompliance with study procedures, need for anticoagulant
therapy and contraindications to the study treatments. The primary end point was the first
occurrence of any of the following events during the six-month follow-up: fatal and nonfatal
AMI, fatal and nonfatal stroke, angina with objective evidence of myocardial ischemia,
vascular death or death due to any other cause.
RESULTS The primary end point was recorded in 59 (8.0%) of the 736 aspirin-treated and 59 (8.0%)
of the 734 ticlopidine-treated patients (p 5 0.966). Vascular death was the first event in five
patients taking aspirin and in six patients taking ticlopidine (0.7% vs. 0.8%; p 5 NS); nonfatal
AMI in 18 and 8 (2.4% vs. 1.1%; p 5 0.049); nonfatal stroke in 3 and 4 (0.4% vs. 0.5%; p 5
NS); and angina in 33 and 40 (4.5% vs. 5.4%; p 5 NS), respectively. The frequency of adverse
reactions was not significantly different between the two groups.
CONCLUSIONS No difference was found between the ticlopidine and aspirin groups in the rate of the primary
combined end point of death, recurrent AMI, stroke and angina. (J Am Coll Cardiol 2001;
37:1259–65) © 2001 by the American College of Cardiology
Both aspirin and ticlopidine have proved to be beneficial in
patients with atherosclerotic disease, with relative risk re-
ductions of 27% and 33%, respectively, in terms of the
composite end point of vascular death, acute myocardial
infarction (AMI) and stroke (1). In coronary artery disease
(CAD), the beneficial effect of aspirin extends to a wide
range of clinical conditions, including suspected AMI,
postinfarction, stable and unstable angina and coronary
artery bypass graft surgery (2). Ticlopidine has been shown
to be beneficial in unstable angina (3), bypass surgery (4)
and, in combination with aspirin, in reducing the risk of
subacute stent thrombosis (5).
In current clinical practice, aspirin is the standard anti-
platelet therapy in secondary prevention after MI (6).
However, aspirin is a weak platelet inhibitor and is not
protective against recurrent ischemic events in a sizable
number of patients with CAD (1,7–9). Progression of CAD
or mechanisms overcoming the platelet inhibitor effect of
aspirin may be responsible for such recurrences (8,10).
Adenosine diphosphate (ADP) inhibitors are currently used
as an alternative to aspirin, but the role of ticlopidine in
secondary prevention after AMI has not yet been explored.
The present study compares the efficacy and safety of aspirin
and ticlopidine in survivors of AMI treated with thrombo-
lysis.
METHODS
This was a randomized, double-blind, multicenter trial
managed by a Coordinating and Data Management center,
as well as Steering, Safety and Validation Committees. All
events and adverse reactions were reviewed by the Valida-
tion and Safety Committees in blinded manner. The study
protocol was approved by local Ethical Committees, and all
patients gave written, informed consent.
Patients. Eligible patients were men and women .18 years
old who had been discharged from the hospital after a MI
treated with thrombolytic therapy, with the onset of MI no
more than 30 days before randomization. Acute MI was
diagnosed by the presence of at least two of the following:
typical chest pain lasting .30 min; an increase in creatine
kinase, aspartate transaminase or lactate dehydrogenase
levels to at least twice the upper limit of normal; ST
segment elevation $0.1 mV in any limb lead on the
electrocardiogram (ECG) on admission to the coronary care
unit or $0.2 mV in at least two contiguous precordial leads,
or both; or the presence of new Q-waves lasting $40 ms in
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at least two contiguous ECG leads, or a new dominant
R-wave in lead V1 (R-wave $1 mm $S in lead V1) on the
prerandomization ECG. Exclusion criteria were contrain-
dications to the study drugs (e.g., hematopoietic or hemo-
static disorders, a history of thrombocytopenia, leukopenia
or peptic ulcer); the need for oral anticoagulant therapy;
scheduled major or bypass surgery; severe comorbidity likely
to limit the patient’s life expectancy; uncontrolled hyperten-
sion; geographic or other factors making study participation
impractical; or participation in other concomitant trials.
Each center recorded all consecutively screened patients
who had thrombolysis in a log book, and checked the
inclusion and exclusion criteria and reported their in-
hospital outcomes.
Study protocol. The initial assessment included a medical
history, general physical and cardiovascular examination and
recording details of the qualifying AMI. Laboratory tests
were carried out at baseline to rule out excluding conditions.
The clinical follow-up visits took place after 45 days, three
months and at the end of the six-month follow-up period.
During these visits, information was collected on outcome
end points, adverse events and concomitant medications,
and the study drug for the next period was dispensed. Blood
cell counts were repeated every two weeks during the first
three months, then at each scheduled visit.
Compliance was assessed by counting the number of
tablets returned at each follow-up visit, which was recorded
in the case report form. Patients were given indistinguish-
able blister packs containing either ticlopidine (250-mg
tablets) or plain aspirin (80-mg tablets), and they were asked
to take one tablet twice a day after meals. The use of
anticoagulants or additional antiplatelet agents was forbid-
den, and patients were instructed to avoid aspirin-
containing products. If surgery was scheduled, the study
drug was discontinued 10 days before and then resumed. All
reasons for early, temporary or permanent discontinuation
were recorded. The patients were to be followed up for six
months, regardless of whether or not they were still taking
the study drug.
End points and outcome events. The primary end point
was the first occurrence of any of the following during the
six-month follow-up period: fatal and nonfatal MI, fatal
and nonfatal stroke, angina with objective evidence of
myocardial ischemia, vascular death or death due to any
other cause. Nonfatal MI was diagnosed by the presence of
at least two of the following: typical chest pain lasting
.30 min; increases in cardiac enzyme levels to at least twice
the upper limit of normal; new and persistent ST segment
elevations in any ECG leads; or new pathologic Q-waves, as
described earlier. Nonfatal ischemic stroke was defined as a
suddenly occurring focal neurologic deficit lasting .24 h
whose ischemic origin was confirmed by a cerebral com-
puted tomographic scan or magnetic resonance imaging.
Angina could be considered as an outcome event, pro-
vided it was documented by ECG changes during or just
after the chest pain and/or Holter, ergometric or myocardial
scintigraphy abnormalities demonstrating myocardial isch-
emia. Fatal reinfarction or ischemic stroke was diagnosed if
death occurred within 28 days of the acute event. Vascular
death, including sudden death, was any death clearly not
due to nonvascular causes. Thrombocytopenia was defined
as serious when the platelet count was ,80,000/mm3, and
neutropenia was diagnosed when the neutrophil count was
,450/mm3.
Sample size. It was estimated that ;2,500 patients had to
be treated and followed up for six months to detect a 5%
absolute difference in the frequency of patients free of any of
the events considered in the primary end point (alpha 5
0.05, two-sided; power 0.85).
When the study was planned, thrombolysis was expected
in 70% of patients with MI (11), and a frequency of 75% in
event-free patients was assumed as the baseline reference
value (12–15). Therefore, a recruitment period of 12
months was decided. During the screening process, it
became evident that the actual proportion of thrombolysed
patients was ;40%, and consequently the recruitment
period was extended to 22 months, but it was still not long
enough to recruit the planned number. Furthermore, during
the study, the overall frequency of event-free patients
(monitored in blinded manner) was always ;90%. After
recruitment of 1,470 patients, the power calculation was
revised, using the observed event-free frequency of 90% as
baseline, with 5% as the absolute difference between groups
(alpha 5 0.05, two-sided test); a power of 95% was reached.
Statistical analysis. Intention-to-treat analysis was done
by evaluating all the enrolled patients and all the validated
outcome events. Primary analysis was based on the first
occurrence of an event in the outcome cluster of death, MI,
ischemic stroke and angina. Event-free time analysis was
done using the log-rank two-sided test, and event-free
survival curves were plotted using the Kaplan-Meier
method. Time was calculated as the time that a patient
participated in the trial, measured in days from the date of
randomization to the date of the occurrence of the primary
end point, or from the date of randomization to sixth-
month follow-up of patients who were event-free. Accord-
ing to the protocol, all possible efforts were made to obtain
complete follow-up information up to the end of the trial
for patients who discontinued early. The following censor-
ing procedure was adopted: “withdrawal event-free” patients
at the end of the six-month trial; and “lost to follow-up”
patients at the last available follow-up visit.
When a patient is exposed to several causes of heart
failure, the occurrence of each can be analyzed by making
Abbreviations and Acronyms
ADP 5 adenosine diphosphate
AMI 5 acute myocardial infarction
CAD 5 coronary artery disease
ECG 5 electrocardiogram
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allowance for the “competing risk” of the event considered
(16). As allowed in the protocol, a further analysis was
planned to investigate the possible different effects of treat-
ments on each type of primary event. The crude cumulative
incidences were calculated for three types of failure: nonfatal
MI, angina (added with the few cases of nonfatal stroke)
and death for any reason. Gray’s nonparametric method
(17,18) was used to compare the crude cumulative inci-
dences of each type of failure.
Safety assessments were based on the proportions of
patients experiencing one or more episodes of a specific
drug-related adverse event, and comparisons were made by
using the chi-square test. All adverse events (serious and
nonserious) were reported, as grouped by body system
according to World Health Organization Adverse Reaction
Terminology. A patient was counted only once in the total
for a body system, regardless of the number of individual
events reported within that system.
RESULTS
Screening. Between March 1995 and January 1997, 4,696
patients with AMI treated with thrombolysis were screened
for inclusion in the trial. Of these, 261 patients (5.6%) died
in the hospital and 1,470 were randomized to receive aspirin
(n 5 736) or ticlopidine (n 5 734). The most frequent
reasons for exclusion were refusal to give informed consent
(25%), planned myocardial revascularization (14%), risk of
noncompliance with study procedures (14%), need for
anticoagulant therapy (5.3%) and contraindications to the
study treatments (5.2%). The baseline characteristics of the
1,470 patients enrolled are listed in Table 1, and those at
randomization in Table 2. In both groups, 96% of the
patients met all the three diagnostic criteria for qualifying
AMI. The early-phase treatments are reported in Table 3.
End point. During the six-month follow-up, the primary
end point (defined as the first occurrence of death, nonfatal
MI or stroke or angina) occurred in 118 patients: 59 in the
ticlopidine group and 59 in the aspirin group. The frequen-
cies of the first events are presented in Table 4, and the
cumulative incidence curves are shown in Figure 1. Five of
these 59 patients in the aspirin group and six in the
ticlopidine group experienced more than one event. In the
aspirin group, one patient died late (.28 days) after MI;
one died late after MI and documented angina; one had MI
after angina; one presented with angina after MI; and one
patient had angina recorded three times. In the ticlopidine
group, one patient died late after MI; one died late after
documented angina; and four presented with angina twice.
To investigate whether the treatments had different
effects on the individual type of event, the crude cumulative
incidence was estimated for each (Fig. 2). The curves for
fatal events (Fig. 2A) were similar over time (p 5 0.558).
The crude cumulative incidence curves for nonfatal MI (Fig.
2B) started to diverge at day 20 and maintained this
difference throughout the follow-up, showing more effective
protection with ticlopidine (p 5 0.049). The curves for
angina and nonfatal stroke (Fig. 2C) diverged after the first
month of treatment, but tended to converge toward the end
of the follow-up period (p 5 0.342). The rate of revascu-
larization during follow-up was 13% in both groups.
Table 1. Baseline Characteristics of All Patients Enrolled
Aspirin Group
(n 5 736)
Ticlopidine Group
(n 5 734)
Males 84.6% 83.0%
Age (yrs) 58.7 6 10.3 59.8 6 10.5
Hypertension 33.4% 33.9%
Diabetes 14.3% 15.7%
Hyperlipidemia 33.7% 38.4%
Current smokers 52.7% 51.1%
Previous MI 8.0% 8.4%
Previous angina 33.3% 33.9%
Previous cerebrovascular disease 1.8% 2.5%
Previous peripheral arterial disease 6.1% 5.7%
Data are presented as the percentage of patients or mean value 6 SD. None of the
differences were significant.
MI 5 myocardial infarction.
Table 2. Patients’ Main Characteristics at Randomization
Aspirin Group
(n 5 736)
Ticlopidine Group
(n 5 734)
Time to discharge (days) 11.3 6 3.6 11.6 6 4.1
Time to randomization (days) 12.7 6 6.3 12.8 6 5.7
Infarct location
Anterior 36.9% 35.4%
Inferior 54.0% 57.0%
Other 9.1% 7.6%
NYHA class I 90.1% 89.9%
Mean LVEF (%) 52.2 52.6
LVEF ,40% 7.6% 7.1%
High risk patients* 26.2% 26.4%
Medications
ACE inhibitors 52.7% 52.7%
Beta-blockers 45.5% 47.0%
Calcium antagonists 17.0% 17.0%
Statins 6.1% 8.0%
*Patients .70 years, with early left ventricular failure or ejection fraction ,40%. Early
left ventricular failure was defined as either Killip class .2 or the appearance of new
symptoms and signs of left ventricular failure within the fourth day after admission to
coronary care unit. Data are presented as the mean value 6 SD or percentage of
patients, except for mean LVEF (%). None of the differences were significant.
ACE 5 angiotensin-converting enzyme; LVEF 5 left ventricular ejection
fraction; NYHA 5 New York Heart Association.
Table 3. Acute-Phase Treatment in the Hospital
Aspirin Group
(n 5 736)
Ticlopidine Group
(n 5 734)
Thrombolysis within 3 h 68.7 67.4
t-PA 65.4 66.1
Streptokinase 25.4 25.3
Other thrombolytic agents 9.2 8.6
Heparin 92.0 91.6
Aspirin 92.8 94.4
ACE inhibitors 53.4 53.4
Beta-blockers 50.7 50.9
Data are presented as the percentage of patients. None of the differences were
significant.
ACE 5 angiotensin-converting enzyme; t-PA 5 tissue plasminogen activator.
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Trial withdrawals. Of the 1,470 randomized patients, 333
(22.6%) permanently discontinued the study drug before the
end of the scheduled six-month follow-up period: 152 in the
aspirin group and 181 in the ticlopidine group (p 5 0.07).
Of these patients, 271 were observed until the end of the
trial; 30 (4.1%) in the aspirin group and 32 (4.4%) in the
ticlopidine group were lost to follow-up. Thirty-five pa-
tients in the aspirin group and 53 in the ticlopidine group
stopped the treatment because of adverse events; 26 in the
aspirin group and 21 in the ticlopidine group withdrew
because of the occurrence of an end point.
Adverse reactions. Of the 1,470 randomized patients, 162
(11%) reported at least one drug-related adverse event: 72
(9.8%) in the aspirin group and 90 (12.3%) in the ticlopidine
group (p 5 0.129). Serious adverse events occurred in 11
patients (1.5%) treated with aspirin (one of whom presented
with two serious reactions: chest pain and dyspepsia) and 18
(2.4%) treated with ticlopidine (p 5 0.196). The most
frequent or meaningful adverse events (classified by organ
system) are reported in Table 5.
For gastrointestinal symptoms, the following frequencies
were found in the aspirin group and ticlopidine group,
respectively: abdominal pain (3.4% and 3.3%), dyspepsia
(2.0% and 1.9%), diarrhea (0.4% and 1.4%), nausea (0.3%
and 0.5%) and melena in two patients treated with aspirin
(0.3%). Eight adverse events in the aspirin group were
serious (1.1%): seven required hospital admission (abdom-
inal pain [n 5 2], dyspepsia [n 5 2], melena [n 5 1],
pancreatitis [n 5 1] and hemorrhagic gastric ulcer [n 5 1]);
the eighth event was defined as medically serious nausea. In
the ticlopidine group, 11 adverse events (1.5%) were serious
and required hospital admission (abdominal pain [n 5 3],
dyspepsia [n 5 4], diarrhea [n 5 1], gastritis [n 5 1],
duodenal ulcer [n 5 1]and gastric ulcer [n 5 1]).
Platelet, bleeding and clotting disorders developed in
seven patients treated with aspirin: thrombocytopenia (n 5
3, one serious), gingival bleeding (n 5 2), epistaxis (n 5 1)
and hematoma (n 5 1). In the ticlopidine group, the
complication included epistaxis (n 5 3), thrombocytopenia
(n 5 4, one serious) and hematoma (n 5 1). Aspirin was
discontinued in four patients (bleeding [n 5 1], hematoma
[n 5 1] and thrombocytopenia [n 5 2]), and ticlopidine was
discontinued in five patients (thrombocytopenia [n 5 3] and
epistaxis [n 5 2]). There were no cases of cerebral bleeding.
White blood cell and reticuloendothelial system disorders
occurred in one patient taking aspirin and in four patients
taking ticlopidine. Two of those in the ticlopidine group
had serious cases (one case of leukopenia and one of
granulocytopenia), but both patients recovered without
sequelae. One case of serious anemia occurred in the aspirin
group, and one case of serious pancytopenia occurred in the
ticlopidine group. In addition, four other serious adverse
events were reported: one rash in the aspirin group and one
case of rash, one case of elevated hepatic enzymes and one
case of pulmonary infiltration in the ticlopidine group.
DISCUSSION
To the best of our knowledge, this is the first study
comparing the effects of ticlopidine and aspirin on recurrent
events after thrombolysis in patients with AMI. The dose of
160 mg/day of aspirin was chosen on the basis of the Second
International Study of Infarct Survival (ISIS-2) results (19).
This choice is consistent with the American College of
Cardiology/American Heart Association (6) recommenda-
tion that a dose of 160 to 325 mg should be given on day 1
of AMI and continued indefinitely on a daily basis there-
after. At 160 mg/day, aspirin has a rapid clinical antithrom-
botic effect caused by immediate and near-total inhibition of
thromboxane A2 production (6); furthermore, the likelihood
of side effects is low.
The main finding of the trial was that the incidence of the
primary combined end point of vascular death, nonfatal MI
or stroke or angina was no different between the two groups.
However, the data also suggest that the risk of reinfarction
after thrombolysis may be lowered further by ticlopidine
(p 5 0.049). It is worth noting that the incidence of
nonfatal reinfarction in the aspirin-treated patients (2.4%)
in the present study was very close to that in the Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto
miocardico-2 (GISSI-2) trial (2.5%) (20), despite a substan-
tially greater use of aspirin (100% vs. 77%), beta-blockers
(46% vs. 25%), angiotensin-converting enzyme inhibitors
(53% vs. 10%) and revascularization procedures (13% vs.
6%) in our six-month follow-up study versus GISSI-2,
respectively. Our results are consistent with the findings of
the Studio della Ticlopidina nell’Angina Instabile trial
Figure 1. Incidence curves for primary end point.
Table 4. Primary End Point
Aspirin Group
(n 5 736)
Ticlopidine Group
(n 5 734)
Cardiovascular death 5 (0.7%) 6 (0.8%)
Nonvascular death — 1 (0.1%)
Nonfatal myocardial infarction 18 (2.4%) 8 (1.1%)
Nonfatal stroke 3 (0.4%) 4 (0.5%)
Documented angina 33 (4.5%) 40 (5.4%)
Total 59 (8.0%) 59 (8.0%)*
*p 5 0.966 as compared with aspirin group. Data are presented as the number (%) of
patients.
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(STAI) (3), in which the benefit of ticlopidine was entirely
due to the lower incidence of fatal or nonfatal AMI. They
are also in line with the more recent Clopidogrel versus
Aspirin in Patients at Risk of Ischemic Events (CAPRIE)
trial (21), which compared clopidogrel with aspirin in
patients at risk of ischemic events. In that study, there was
a relative risk reduction of 8.7% (p 5 0.043) for the primary
outcome cluster of MI, ischemic stroke and vascular death
and 19.2% for the outcome of MI alone, in favor of
clopidogrel.
Reinfarction after thrombolysis. Most reinfarctions oc-
curring late after thrombolysis (.1 month) result from
reocclusion of the infarct-related artery (22–24). White et
al. (25) found that reocclusion occurred between four weeks
and one year in 25% of the patients who had successful
thrombolysis and was clinically associated with reinfarction
in almost half of the cases. The severity of residual stenosis
proved to be a strong independent predictor of reocclusion
in the year after successful thrombolysis (25–27).
In patients with severe residual stenosis, the rheology of
blood flow in the vessel is altered, leading to increased shear
stress and rethrombosis (28). Experimental studies have
shown the limited efficiency of aspirin in inhibiting platelet-
mediated thrombosis under high shear conditions (29–31).
In agreement with these experimental findings, angio-
graphic studies have shown only a limited benefit of aspirin
in preventing late reocclusion of severe infarct-related artery
stenoses after thrombolysis (25,27). Aspirin appears to
protect against reocclusion of the less severe lesions, but
these have a lower reocclusion rate anyway (25,27).
Figure 2. Crude cumulative incidence curves for death (A), nonfatal repeat myocardial infarction (B) and angina or nonfatal stroke (C).
Table 5. System Organs With Serious Adverse Events
System/Organ Class
All Adverse
Drug Reactions
Serious Adverse
Drug Reactions
Study Drug
Permanently Discontinued
Aspirin Ticlopidine Aspirin Ticlopidine Aspirin Ticlopidine
Gastrointestinal system 54 (7.3%) 64 (8.7%) 8 (1.1%) 11 (1.5%) 30 (4.1%) 30 (4.1%)
Platelet, bleeding and clotting disorders 7 (0.9%) 8 (1.1%) 1 (0.1%) 1 (0.1%) 4 (0.5%) 5 (0.7%)
White cell and RES 1 (0.1%) 4 (0.5%) — 2 (0.3%) — 4 (0.5%)
Red blood cell 1 (0.1%) 1 (0.1%) 1 (0.1%) 1 (0.1%) 1 (0.1%) 1 (0.1%)
Body as a whole (general disorders) 2 (0.3%) 2 (0.3%) 1 (0.1%)* — 1 (0.1%) 2 (0.3%)
Skin and appendages 5 (0.7%) 14 (1.9%) 1 (0.1%) 1 (0.1%) 3 (0.4%) 13 (1.8%)
Liver and biliary system — 3 (0.4%) — 1 (0.1%) — 1 (0.1%)
Respiratory system 1 (0.1%) 3 (0.4%) — 1 (0.1%) — 3 (0.4%)
*This event (chest pain) occurred in a patient who also had serious dyspepsia. Data are presented as the number (%) of patients.
RES 5 reticuloendothelial system.
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Under the high shear rate situations characteristic of
severe stenosis, ADP plays an important role in mediating
platelet aggregation (7,32,33), and ADP inhibitors have
shear-independent antithrombotic effects in an experimen-
tal setting (30,31,34). It has not been determined whether
this translates into a greater benefit of ADP inhibitors in
preventing late reocclusion of the infarct-related artery, and
its deleterious consequences (26), after thrombolysis. The
lower reinfarction rate found in the present study is prom-
ising.
Side effects. The incidence of drug-related adverse events
did not differ significantly between the two groups. The
most frequent were gastrointestinal disorders, which oc-
curred in 7.3% of patients in the aspirin group and 8.7% of
patients in the ticlopidine group. There were few serious
side effects in either group; serious reversible neutropenia
was observed in only two patients, both of whom were
taking ticlopidine (0.3%). This rate is lower than that
previously reported, and several reasons are possible: labo-
ratory tests were done at baseline to rule out contraindica-
tions to the study drugs; ticlopidine was permanently
discontinued in two additional patients presenting with
mild neutropenia, which otherwise might have become
severe; and, at present, all physicians are aware of the
potential adverse effects associated with ticlopidine, and
consequently, they pay careful attention to hematologic
monitoring to detect any such effect promptly.
Study limitations. Overall, we found no difference in the
frequency of the primary end point between the two
treatment arms. However, there was a significantly lower
rate of nonfatal reinfarction in the ticlopidine group (p 5
0.049). Although the analysis aimed at assessing the effects
of treatment on each type of failure combined in the primary
end point had been planned by protocol, this finding must
be viewed with some caution. The trial was not powered to
detect a difference in the reinfarction rate between the two
groups, and the number of reinfarctions was low. Further-
more, the mechanisms underlying rethrombosis are multi-
factorial (29).
Conclusions. Despite an apparent trend toward a lower
reinfarction rate with ticlopidine, the frequency of the
primary combined end point of death, reinfarction, stroke
and angina was no different between the two treatment
groups. These data indicate that an ADP inhibitor, such as
ticlopidine, is at least as effective as aspirin in preventing
recurrent events in post-MI patients treated with thrombo-
lysis.
APPENDIX
STAMI Study Organization: STEERING COMMITTEE: P.
Rizzon (Chairman), D. Scrutinio, C. Cimminiello, E.
Marubini, G. Rudelli, G. Feruglio> ; VALIDATION COMMIT-
TEE: D. Scrutinio, C. Cimminiello, C. Pasotti, A. Carolei;
OUTCOME EVALUATION COMMITTEE: E. Marubini, G.
Serio; SAFETY COMMITTEE: G. G. Nenci, M. Guslandi;
DATA MANAGEMENT: A. Passannante; STATISTICAL ANAL-
YSIS: S. Geraci.
For a complete list of Collaborating Clinical centres,
please see the April issue of JACC at www.cardiosource.com.
Reprint requests and correspondence: Dr. Domenico Scrutinio,
Division of Cardiology, “S. Maugeri” Foundation, IRCCS, Insti-
tute of Rehabilitation, 70020 Cassano Murge, Bari, Italy. E-mail:
dscrutinio@fsm.it.
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